Kyntra Bio (KYNB) Operating Expenses (2014 - 2026)
Kyntra Bio (KYNB) posted Operating Expenses of $17.6 million for Q1 2026, up 18.71% sequentially from $14.8 million in Q4 2025, and down 0.58% YoY from $17.7 million in Q1 2025.
Kyntra Bio (KYNB) Operating Expenses (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Operating Expenses for 13 years, with the latest figure at $17.6 million in Q1 2026.
- Quarterly Operating Expenses fell 0.58% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.2 million (down 57.59% YoY) and the FY2025 annual result came in at $52.3 million, down 70.93% from the prior year.
- Operating Expenses improved to $17.6 million in Q1 2026 per KYNB's latest filing, from $14.8 million in the prior quarter.
- Over five years, Operating Expenses peaked at $132.4 million in Q2 2023 and troughed at $6.5 million in Q3 2025.
- A 5-year average of $62.4 million and a median of $47.8 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 44.03% in 2025, down 86.43% in 2025.
- Over 5 years, Operating Expenses stood at $100.5 million in 2022, then sank by 78.82% to $21.3 million in 2023, then tumbled by 51.77% to $10.3 million in 2024, then soared by 44.03% to $14.8 million in 2025, then advanced by 18.71% to $17.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $17.6 million, $14.8 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn | 16.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.10 Mn |
| Mar 31, 2026 | 17.56 Mn |
| Dec 31, 2025 | 14.79 Mn |
| Sep 30, 2025 | 6.49 Mn |
| Jun 30, 2025 | 13.40 Mn |
| Mar 31, 2025 | 17.66 Mn |
| Dec 31, 2024 | 10.27 Mn |
| Sep 30, 2024 | 47.82 Mn |
| Jun 30, 2024 | 47.41 Mn |
| Mar 31, 2024 | 74.55 Mn |
| Dec 31, 2023 | 21.29 Mn |
| Sep 30, 2023 | 103.62 Mn |
| Jun 30, 2023 | 132.37 Mn |
| Mar 31, 2023 | 112.25 Mn |
| Dec 31, 2022 | 100.52 Mn |
| Sep 30, 2022 | 109.39 Mn |
| Jun 30, 2022 | 108.03 Mn |
| Mar 31, 2022 | 123.82 Mn |
| Dec 31, 2021 | 151.78 Mn |
| Sep 30, 2021 | 105.00 Mn |